+27 (0)83 440 0793 mark.fyvie@vxpharma.com
Select Page
...A RANGE OF NEXT GEN OFFERINGS......A RANGE OF NEXT GEN OFFERINGS...

ADVANCED THERAPEUTICS

ADVANCED THERAPEUTICS

SELL • FINISH • INVENT
SELL • FINISH • INVENT
FIND OUT MOREFIND OUT MORE
• Gene & cell therapies
• Nucleic acid based vaccines
• Targeted immunotherapies
• Gene & cell therapies
• Nucleic acid based vaccines
• Targeted immunotherapies
...COMBINING BIOTECH AND INFOTECH......COMBINING BIOTECH AND INFOTECH...

DISRUPTIVE HEALTH INTELLIGENCE

DISRUPTIVE HEALTH INTELLIGENCE

FIND OUT MOREFIND OUT MORE
• Insilco biomarker discovery
• Patient-centric eHealth solutions
• Democratised EMR and genomic datasets
• Insilco biomarker discovery
• Patient-centric eHealth solutions
• Democratised EMR and genomic datasets
SELL • FINISH • INVENT
SELL • FINISH • INVENT
AVAILABLE NOWAVAILABLE NOW

BIOPHARMA ADVISORY

BIOPHARMA ADVISORY

FIND OUT MOREFIND OUT MORE
• Business strategy
• Business concept design
• Investment facilitation and closure
• Startup incubation and mentorship
• Clinical development facilitation and strategy
• Business strategy
• Business concept design
• Investment facilitation and closure
• Startup incubation and mentorship
• Clinical development facilitation and strategy

Our journey so far…

For over a decade, from the initial round of seed funding that enabled us to enter the clinical trials space in 2010, to the sale of our ongoing site operations in 2020, Vx Pharma has earned a reputation for integrity, innovation, and excellence.

Now, at the dawn of our second decade, the vision of our founder Dr. Mark Fyvie is of a leading contributor and pioneer, capitalising on the revolutionary ICT- and biotechnologies now disrupting the diagnostics, therapeutics, health intelligence, and clinical research sectors. 

To achieve those aims, Vx Pharma has been fundamentally restructured, to enable us to sell, finish, and invent in our four selected focus areas.

Over the coming months, we will announce a range of exciting new projects, products and services, and welcome inquiries from investors, partners, and buyers.

First round of seed funding

Series ‘A’ VC round by Industrial Development Corporation

Build out of super-site operations at the Innovation Hub

Series ‘B’ VC round by Ampath TLC

Restructured business acquired by founder and sale of site operations

About Mark Fyvie (PhD, Cambridge University)

 Mark Fyvie on Linkedin

Mark Fyvie is a biotechnology entrepreneur, the founder of Vx Pharma and currently its sole shareholder. Prior to Vx Pharma, Mark served as CEO and founding member of the Cape Biotech Investment Trust, funding and incubating VC investments in excess of $100 million in new life-science ventures. An internationally accredited business strategy consultant, Mark has helped develop commercial strategies for innovators in pharmaceutical, biotech, clinical research, and e-finance organisations, including FirstRand Bank, Liberty Health and Accenture. Mark serves on numerous boards and donates significant time to pro bono work in the South African innovation ecosystem.

 

OUR CLIENTS

CONTACT US

Things have changed, and we’re moving forward.

If you’re new to Vx Pharma, you’ll find details of who we are, on this website.

If you already know who we are, read on to discover how our focus is changing and what we have in store going forward!